Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: ASCO clinical practice guideline update-integration of results from TAILORx

Fabrice Andre, Nofisat Ismaila, N. Lynn Henry, Mark R. Somerfield, Robert C. Bast, William Barlow, Deborah E. Collyar, M. Elizabeth Hammond, Nicole M. Kuderer, Minetta C. Liu, Catherine Van Poznak, Antonio C. Wolff, Vered Stearns

    Résultats de recherche: Contribution à un journalArticle 'review'Revue par des pairs

    185 Citations (Scopus)

    Résumé

    PURPOSE This focused update addresses the use of Oncotype DX in guiding decisions on the use of adjuvant systemic therapy. METHODS ASCO uses a signals approach to facilitate guideline updating. For this focused update, the publication of the Trial Assigning Individualized Options for Treatment (TAILORx) evaluating noninferiority of endocrine therapy alone versus chemoendocrine therapy for invasive disease-free survival in women with Oncotype DX scores provided a signal. An expert panel reviewed the results of TAILORx along with other published literature on the Oncotype DX assay to assess for evidence of clinical utility. UPDATED RECOMMENDATIONS For patients with hormone receptor-positive, axillary node-negative breast cancer whose tumors have Oncotype DX recurrence scores of less than 26, there is little to no benefit from chemotherapy, especially for patients older than age 50 years. Clinicians may recommend endocrine therapy alone for women older than age 50 years. For patients 50 years of age or younger with recurrence scores of 16 to 25, clinicians may offer chemoendocrine therapy. Patients with recurrence scores greater than 30 should be considered candidates for chemoendocrine therapy. Based on informal consensus, the panel recommends that oncologists may offer chemoendocrine therapy to these patients with recurrence scores of 26 to 30. Additional information can be found at www.asco.org/breast-cancer-guidelines.

    langue originaleAnglais
    Pages (de - à)1956-1964
    Nombre de pages9
    journalJournal of Clinical Oncology
    Volume37
    Numéro de publication22
    Les DOIs
    étatPublié - 1 août 2019

    Contient cette citation